Is There a Wegovy Pill in the UK and Is It Available in Bishops Stortford?

A Wegovy pill is now a reality in the UK, following a landmark regulatory decision that marks a genuinely new chapter in medically supported weight management. On 11 June 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved oral semaglutide tablets for weight management, making it the first daily GLP-1 weight loss pill ever licensed in the UK and representing a significant advance in accessible treatment options for patients who are unable or unwilling to self-inject. The oral formulation contains the same active ingredient — semaglutide — as the injectable Wegovy pen, but delivers it in a once-daily tablet form that many patients are likely to find considerably more convenient and less daunting than a weekly injection. While the injectable form of Wegovy remains available and continues to be prescribed, the arrival of an oral option opens up medically supported weight loss to a broader range of patients than ever before. The clinical team at J E Williamson Pharmacy in Bishops Stortford is actively tracking the rollout of oral semaglutide and is on hand to help every patient assess whether this new treatment option is the right fit for their individual health needs and lifestyle.

How Does the Wegovy Pill Work?

Oral semaglutide for weight management works through the same fundamental mechanism as its injectable counterpart — by activating GLP-1 receptors in the brain and gut to reduce appetite, slow gastric emptying, and improve blood sugar regulation. The key difference lies in the delivery method: rather than a once-weekly subcutaneous injection, the oral formulation is taken as a once-daily tablet. The oral tablet uses a proprietary absorption technology that allows semaglutide — a peptide that would otherwise be degraded in the stomach — to be absorbed through the gut wall in sufficient quantities to produce a clinically meaningful effect. This absorption technology is the same that underpins the existing oral semaglutide formulation already licensed for type 2 diabetes (Rybelsus), which has an established real-world safety and efficacy profile. It is important to note that the oral and injectable forms of semaglutide use fundamentally different dose levels and cannot be compared on a mg-for-mg basis — oral bioavailability of semaglutide is approximately 1%, meaning the oral formulation requires significantly higher nominal doses to achieve a comparable systemic exposure to the injectable form.

Comparing the Wegovy Pill and Injection

The most important question for many patients considering the Wegovy pill will be how it compares in terms of effectiveness to the injectable pen. The clinical data available for oral semaglutide in weight management is still accumulating as the product is newly approved, and direct head-to-head trial comparisons with injectable Wegovy specifically for the weight management indication are not yet publicly available. The existing injectable Wegovy has an established average weight loss of approximately 15% of body weight at 68 weeks in the STEP-1 trial. Because oral bioavailability of semaglutide is approximately 1% — meaning the oral and injectable forms use fundamentally different dose levels and should not be directly compared on a mg-for-mg basis — the weight management formulation has been specifically developed and dosed to optimise oral bioavailability for this indication. Your prescribing clinician is best placed to advise on the most appropriate formulation for your individual circumstances based on the latest available evidence.

Who Should Consider the Wegovy Pill?

The arrival of an oral GLP-1 weight loss medication is particularly significant for several groups of patients who may have been less well-served by injectable options. Patients who are needle-averse — and there are many — may find that the availability of a daily pill removes the single biggest barrier to accessing medically supported weight loss treatment. Those with busy or unpredictable schedules may also appreciate the flexibility of a daily tablet over a weekly injection that requires storage and administration with a pen device. Additionally, the psychological barrier of self-injecting can be significant, and the normalisation of a pill format may make the treatment feel more accessible and less medicalised for patients who are new to prescription weight loss treatment. That said, the injectable form continues to have a well-established efficacy and safety profile, and for many patients it will remain the preferred or most clinically appropriate option.

How to Take the Wegovy Pill

Correct administration of oral semaglutide is particularly important because the bioavailability of the tablet is significantly affected by how and when it is taken. The tablet must be swallowed whole — never crushed or chewed — with a small amount of plain water, on an empty stomach, first thing in the morning. Nothing else should be eaten, drunk, or taken orally for at least 30 minutes after swallowing the tablet, as food, drink, and other medications all significantly reduce the absorption of semaglutide through the gut wall. Always follow the specific administration instructions provided with your prescription, as requirements may differ from other oral semaglutide products — your prescribing clinician or pharmacist will confirm the exact administration guidance applicable to your treatment. Establishing a consistent morning routine around the tablet is one of the most practical steps a patient can take to maximise the benefit of oral semaglutide from day one.

With the practical side of oral semaglutide covered, understanding your personal weight loss potential is the next motivating piece of the picture.  Enter your height and weight into our calculator below to discover how much you could potentially lose with Wegovy or Mounjaro:

Wegovy Pill Availability in the UK

Following MHRA approval on 11 June 2026, the rollout of oral semaglutide for weight management in the UK is expected to develop progressively through both private prescribers and, in time, NHS pathways. As with injectable Wegovy, private access through licensed prescribers and registered pharmacies is likely to be the most immediately available route for most patients in the near term, while NHS provision develops in line with NICE guidance and commissioning decisions. Eligibility criteria will be confirmed in the approved Summary of Product Characteristics (SmPC) and any associated NICE guidance — speak to a licensed prescriber for the most current and accurate eligibility information, as criteria for the oral formulation should not be assumed to mirror the injectable product exactly. Patients interested in oral semaglutide should speak to their GP or a licensed private prescriber to understand current access options in their area.

Frequently Asked Questions

As interest in the new Wegovy pill grows, the clinical team at J E Williamson Pharmacy in Bishops Stortford has addressed the questions that are coming up most consistently in patient consultations about oral semaglutide for weight management.

Is the Wegovy pill the same as the Wegovy injection?

The Wegovy pill and the Wegovy injection contain the same active ingredient — semaglutide — and work through the same GLP-1 receptor mechanism, but they are distinct products with different formulations, dose levels, administration schedules, and absorption profiles that cannot be compared on a mg-for-mg basis. Your prescribing clinician will advise on which formulation is most appropriate for your individual health profile, lifestyle, and treatment goals.

When will the Wegovy pill be available in the UK?

Oral semaglutide for weight management received MHRA approval on 11 June 2026, and availability through licensed private prescribers and registered pharmacies is expected to develop progressively following this approval. NHS availability will follow in line with NICE guidance and commissioning decisions — speaking to a licensed prescriber or registered pharmacy such as J E Williamson Pharmacy in Bishops Stortford is the most reliable way to find out current access options.

Is oral semaglutide as effective as the injectable Wegovy pen?

The clinical data specifically for oral semaglutide in the weight management indication is still emerging, and direct head-to-head comparisons with injectable Wegovy for this indication are not yet publicly available — the two products also use fundamentally different dose levels due to the approximately 1% oral bioavailability of semaglutide. Your prescribing clinician is best placed to advise on the most appropriate formulation based on the latest available evidence and your individual circumstances.

Can I switch from injectable Wegovy to the pill?

Switching between the injectable and oral formulations of semaglutide may be clinically appropriate for some patients, but should only be done under the guidance of a prescribing clinician who can assess the transition, manage dosing carefully given the different bioavailability profiles, and monitor your response. Never switch between formulations without first consulting your prescriber, as the dosing schedules and administration requirements differ significantly between the two products.

Does the Wegovy pill have the same side effects as the injection?

The side effect profile of oral semaglutide is broadly similar to that of the injectable form, with gastrointestinal effects — including nausea, vomiting, diarrhoea, and constipation — being the most commonly reported. The severity and frequency of these side effects may differ between the two formulations, and your prescribing clinician can advise on what to expect based on your individual health profile and any previous experience with semaglutide.

Do I need a prescription for the Wegovy pill?

Yes — oral semaglutide for weight management is a prescription-only medication in the UK and requires a valid prescription from a registered prescriber following a thorough clinical assessment of your suitability for the treatment. Always access oral semaglutide through a GPhC-registered pharmacy or licensed prescriber and never from unregulated online sources, where the risks of counterfeit or substandard products are significant.

A New Chapter in Weight Loss Treatment

The approval of oral semaglutide for weight management in the UK is a genuinely significant development — one that has the potential to make medically supported weight loss accessible to many patients who were previously unable or unwilling to consider injectable treatment. Whether the Wegovy pill is the right option for you depends on your individual health profile, lifestyle preferences, and clinical circumstances — and those are questions best answered in a thorough consultation with a qualified healthcare professional who has access to the latest approved prescribing information. At J E Williamson Pharmacy in Bishops Stortford, our expert clinical team is committed to staying at the forefront of weight management treatment and helping every patient navigate their options with the clarity, confidence, and personalised support they deserve. Book now and find out whether oral semaglutide or another weight loss treatment is the right next step for your health and your goals.